CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA
07 mars 2024 08h51 HE
|
Curium
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
07 mars 2024 08h51 HE
|
Curium
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
22 févr. 2024 06h19 HE
|
Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer
07 sept. 2023 04h25 HE
|
Curium
PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
Radioactive Tracer Market Worth $54.29 Billion by 2030 - Exclusive Report by The Insight Partners
16 août 2023 08h32 HE
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- A radioactive tracer is a chemical compound in which one or more atoms have been replaced by a radioisotope. Through monitoring its radioactive decay,...
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
15 août 2023 10h50 HE
|
Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
28 juil. 2023 06h12 HE
|
Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
25 juil. 2023 06h06 HE
|
Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
14 mars 2023 10h46 HE
|
Curium
To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
26 janv. 2022 16h51 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...